CTOs on the Move

Neurelis

www.neurelis.com

 
Neurelis, Inc. is a privately-held San Diego-based specialty pharmaceutical company devoted to developing treatment options for epilepsy, while also investigating new treatment options for the unmet needs of central nervous system (CNS) disorders.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.neurelis.com
  • 11682 El Camino Real Suite 255
    San Diego, CA USA 92130
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Neurelis raised $114M on 03/10/2021

Similar Companies

BioSerenity

Solutions connectées pour le diagnostic médical

OSO BioPharmaceuticals Manufacturing

OSO BioPharmaceuticals Manufacturing is a Albuquerque, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Meridian Clinical Research

Meridian conducts clinical trials for drugs, vaccines, and more, but it starts with you — participation makes it all possible. See if youre eligible for a paid research study.

Success TMS

Get relief from depression in under 8 weeks. Safe & FDA approved. Covered by Insurance & Medicare. Get your FREE consultation. Book an appointment Today!

Lyra Therapeutics

Creating precisely tuned medicines so patients can breathe freely, we are pioneering a new therapeutic approach to treat debilitating ear, nose and throat diseases that impact the lives of millions of people. Lyra Therapeutics is a clinical-stage company pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people. Our goal is to transform the ENT treatment paradigm by providing effective front-line solutions for physicians and new treatment options for their patients. Lyra`s transmucosal therapeutic system, now being evaluated in a clinical study, directly targets tissues that are difficult or impossible to access with existing therapies. Building on expertise in materials science, drug development and formulation, the Lyra team has developed a proprietary platform that enables sustained, local delivery of medications over an extended period of time. Based on clinical results, this new therapeutic approach has the potential to provide significantly improved patient outcomes beyond the limited treatment and surgical options currently available for ENT diseases. Headquartered in the Boston area, Lyra Therapeutics was founded by George Whitesides and Robert Langer, academic luminaries in the fields of chemistry, materials science and biotechnology, and is backed by leading life science investors.